← Back

Wire · operational-macro

Bayer brings factor XIa to US stroke prevention with FDA nod for 1st-in-class asundexian

Published

10 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

The FDA approved Bayer's asundexian, the first factor XIa inhibitor drug, for stroke prevention in adults with recent non-cardioembolic ischemic stroke or high-risk TIA, following prior approval in China. This novel oral medicine reduces the risk of ischemic stroke recurrence without increasing major bleeding risks.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You face a new competitor reshaping stroke prevention with an FDA-approved oral drug that reduces recurrence risk without raising bleeding concerns. Adjust your strategy now if your biotech or cardiovascular product overlaps with anticoagulants or stroke therapy.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechstroke-preventionfda-approvalcardiovascularbayeranticoagulants